Table 4 Dynamic clinical and laboratory characteristics of HBV-ACLF patients receiving glucocorticoid treatment.
Parameters | Pre-treatment HBV-ACLF patients (day0, n = 54) | GC-treatment HBV-ACLF patients (day7, n = 54) | GC-treatment HBV-ACLF patients (day28, n = 54) | HCs (n = 24) | |||
|---|---|---|---|---|---|---|---|
Survival (n = 35) | Non-survival (n = 19) | Survival (n = 35) | Non-survival (n = 19) | Survival (n = 35) | Non-survival (n = 19) | ||
Male, n (%) | 42 (77.78) | 42 (77.78) | 42 (77.78) | 17 (70.83) | |||
29 (82.86) | 13 (68.42) | 29 (82.86) | 13 (68.42) | 29 (82.86) | 13 (68.42) | ||
Age (years) | 48 (37–58.25.25) | 48 (37–58.25.25) | 48 (37–58.25.25) | 45.50 (38.75–54.75) | |||
48 (37–55) | 48 (38–60) | 48 (37–55) | 48 (38–60) | 48 (37–55) | 48 (38–60) | ||
HBeAg (+), n (%) | 34 (62.96) | 34 (62.96) | 33 (61.11) | 0 | |||
21 (60) | 13 (68.42) | 21 (60) | 13 (68.42) | 20 (57.14) | 13 (68.42) | ||
Log10 [HBV DNA] (IU/mL) | 4.72 (3.47–5.57) | 4.45 (3.24–5.13) | 4.72 (3.47–5.57) | 0 | |||
4.72 (3.46–5.74) | 4.76 (3.14–5.84) | 4.45 (3.35–5.12) | 4.33 (3.11–5.40) | 4.22 (3.46–4.85) | 4.11 (3.12–5.64) | ||
HBV DNA (+), n (%) | 35 (64.81) | 34 (62.96) | 25 (46.30) | 0 | |||
21 (57.14) | 15 (78.95) | 19 (54.29) | 15 (78.95) | 13 (37.14) | 12 (63.16) | ||
ALT (U/L) | 142.40 (59.75–296)*£§ | 91 (64–128)*& | 62 (44.50–103.25.50.25)* | 20.50 (18–27) | |||
134 (56–264)£§ | 145 (61–362)£§ | 94 (64–127) | 85 (66–133) | 56 (43–85) | 71 (45–139) | ||
TBIL (µmol/L) | 282.25 (187.48–403.78.48.78)*£§ | 236.85 (137.83–349.65.83.65)*& | 134.35 (84.73–263.05.73.05)* | 11.45 (8.75–14.20) | |||
254.50 (169–412.40.40)£§ | 294 (235.70–403.60.70.60) | 150.90 (111.2–310.3.2.3)※ | 287.50 (196.10–407.90.10.90) | 89.60 (63.60–134.70.60.70)※ | 321.20 (256–415.50.50) | ||
ALB (g/L) | 31.75 (28.40–35.08.40.08)*£§ | 35.10 (32.18–38.23)* | 35.85 (33.10–39.48.10.48)* | 46.65 (45.50–49.43.50.43) | |||
31.10 (28.10–35.50)£§ | 33.40 (29.40–35.40)£§ | 34.80 (31.60–38.50) | 35.10 (33.50–37.90) | 36.90 (33.10–40.10) | 33.80 (33.10–37.60) | ||
PTA (%) | 35 (29–44.75.75)*£§ | 41.50 (34–55)*& | 48 (36–75)* | 110 (98–122) | |||
39 (35–52)※£§ | 29 (27–32) | 49 (40–59)※& | 32 (27–39) | 67 (48–79)※ | 32 (25–36) | ||
INR | 2.05 (1.77–2.39)*£§ | 1.88 (1.46–2.06)* | 1.60 (1.18–2.08)* | 0.95 (0.90–1.01) | |||
1.91 (1.62–2.07)※£§ | 2.39 (2.18–2.67) | 1.61 (1.39–1.88)※& | 2.17 (1.96–2.56) | 1.27 (1.14–1.59)※ | 2.22 (2.06–2.57) | ||
MELD score | 19.95 (16.75–23.12)£§ | 17.55 (13.87–21.32)& | 11.88 (8.87–18.18) | NA | |||
17.92(15.36–20.77※£§ | 23.34 (20.83–24.70) | 14.85 (12.22–12.71)※& | 21.24 (20.50–22.14.50.14) | 9.78 (7.74–11.76)※ | 19.90 (17.99–21.81) | ||
HE, n (%) | 12 (22.22)§ | 8 (14.81) | 5 (9.25) | 0 | |||
5 (14.29) | 7 (36.84) | 2 (5.71)※ | 6 (31.58) | 1 (2.86)※ | 4 (21.05) | ||
Ascites, n (%) | 29 (53.70)§ | 25 (46.300) | 19 (35.19) | 0 | |||
18 (51.43) | 11 (57.89) | 14 (40) | 11 (57.89) | 9 (25.71)※ | 10 (52.63) | ||
mRNA (ANXA3) | 0.77 (0.48–1.27)*§ | 0.62 (0.33–0.91)* | 0.41 (0.26–1.02)* | 0.08 (0.03–0.28) | |||
0.65 (0.28–0.85)※£§ | 1.12 (0.90–1.65) | 0.52 (0.14–0.63)※& | 0.94 (0.82–1.54) | 0.33 (0.15–0.41)※ | 1.12 (0.83–1.68) | ||
PMR (ANXA3) | 11.91 (8.16–15.66)*§ | 13.97 (8.51–17.31)* | 14.66 (9.03–19.11)* | 26.34 (18.92–31.59) | |||
14.26 (10.59–16.96)※§ | 8.02 (5.14–9.41) | 14.97 (13.40–17.80)※ | 8.13 (5.51–10.51) | 18.30 (14.06–22.38)※ | 8.25 (6.93–11.42) | ||
